Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany
Open Access
- 8 May 2023
- journal article
- research article
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 38 (1) , 1-10
Abstract
Purpose: Many patients treated for ulcerative colitis (UC) do not achieve clinical remission. This real-world study assessed clinical remission and inadequate response rates among patients with UC in Germany treated with advanced therapies. Methods: This retrospective chart review included patients with UC newly initiating advanced (index) therapy (anti-TNFα agents, vedolizumab, tofacitinib) from January 2017–September 2019 (index date). Included patients had data for ≥ 12 months before (baseline period) and after the index date (follow-up period). Remission was defined as a partial Mayo score ≤ 1. Indicators of inadequate response were: index therapy discontinuation; therapy adjustments (index therapy dose escalation; augmentation with non-advanced therapies; corticosteroid [CS] use during maintenance therapy); CS dependency (use for ≥ 12 weeks); and UC-related hospitalisation, surgery or emergency department visit. Time to first remission and inadequate response were analyzed using Kaplan–Meier analyses. Results: Among 149 patients with UC (median age: 40 years), 96 (64.4%) were biologic-naïve and 42 (28.2%) received CS at the index date. Within 12 months, 52 patients (47.2%) were in remission; of these, 13 patients (25.0%) received ≥ 1 therapy adjustment. At 12 months, 55 patients (37.6%) had ≥ 1 indicator of an inadequate response. Median time to remission was longer among biologic-experienced vs biologic-naïve patients (24 vs 7 months; p = 0.012). Conclusion: Over half of the patients were not in clinical remission after 12 months and more than one-third experienced inadequate response. One-quarter of patients in remission required therapy adjustments. Patients with UC require therapies that are more effective than those currently available to achieve better treatment outcomes.Keywords
Funding Information
- Galápagos
This publication has 17 references indexed in Scilit:
- Indirect costs associated with ulcerative colitis: a systematic literature review of real-world dataBMC Gastroenterology, 2019
- Assessment of steroid use as a key performance indicator in inflammatory bowel disease—analysis of data from 2385 UK patientsAlimentary Pharmacology & Therapeutics, 2019
- Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)Zeitschrift für Gastroenterologie, 2019
- Costs of dose escalation among ulcerative colitis patients treated with adalimumab in GermanyThe European Journal of Health Economics, 2018
- Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel diseaseDigestive and Liver Disease, 2017
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch DisordersJournal of Crohn's and Colitis, 2017
- Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitisWorld Journal of Gastroenterology, 2015
- Health care costs and their predictors of inflammatory bowel diseases in GermanyThe European Journal of Health Economics, 2010
- Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohortAlimentary Pharmacology & Therapeutics, 2010
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008